FY2026 EPS Estimates for Roche Increased by Erste Group Bank

Key Points

• Erste Group Bank raised Roche’s FY2026 EPS forecast to $3.15 from $3.10, above the current consensus estimate of $3.05; its FY2027 estimate is $3.41 per share.
• Analyst sentiment remains mixed, with Roche holding a consensus “Hold” rating and a $60.00 average price target. Recent actions included Morgan Stanley upgrading the stock to “Overweight,” while Zacks Research and HSBC downgraded it.
• Roche shares opened at $57.43 and trade between a 52-week range of $37.51 to $60.85, while several institutional investors recently initiated or increased positions.

Roche Holding AG (OTCMKTS:RHHBY - Free Report) - Stock analysts at Erste Group Bank upped their FY2026 EPS estimates for Roche in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.15 per share for the year, up from their prior estimate of $3.10. The consensus estimate for Roche's current full-year earnings is $3.05 per share. Erste Group Bank also issued estimates for Roche's FY2027 earnings at $3.41 EPS.

RHHBY has been the subject of a number of other reports. Zacks Research downgraded Roche from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 14th. Morgan Stanley upgraded Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price target on the stock in a report on Friday. Finally, HSBC downgraded shares of Roche from a "buy" rating to a "hold" rating in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $60.00.

Roche Stock Performance

Shares of Roche stock opened at $57.43 on Tuesday. Roche has a one year low of $37.51 and a one year high of $60.85. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. The stock's 50-day moving average is $52.27 and its 200 day moving average is $52.90.

Institutional Trading of Roche

Hedge funds have recently bought and sold shares of the business. McIlrath & Eck LLC bought a new stake in Roche during the 1st quarter valued at $39,000. Oakworth Capital Inc. lifted its stake in shares of Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company's stock valued at $86,000 after buying an additional 285 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new position in shares of Roche during the fourth quarter valued at about $192,000. Pinnacle Wealth Management Advisory Group LLC bought a new stake in shares of Roche during the first quarter worth about $208,000. Finally, Enterprise Financial Services Corp increased its position in shares of Roche by 6.6% during the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock worth $277,000 after acquiring an additional 345 shares in the last quarter.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source